People_
Dr Jonathan Danon
MSci (Bris), PhD (Manc)
NHMRC Emerging Leadership Fellow
Address
F11 - Chemistry Building
The University of Sydney
Details
Member of The Centre for Drug Discovery Innovation
Member of the Brain and Mind Centre
Websites
Dr Jonathan Danon is a group leader specialising in synthesis of novel bioactive small molecules at the School of Chemistry. He received his undergraduate degree (MSci in Chemistry with Industrial Experience) from the University of Bristol in 2011, spending one year of his degree working for AstraZeneca. Funded by an EaStCHEM Studentship, he undertook a PhD in Chemistry and subsequent postdoctoral position with Prof. David Leigh FRS at the University of Edinburgh/University of Manchester from 2011–16. After moving to Australia in 2017 to kickstart his academic medicinal chemistry career, he won a University of Sydney Postdoctoral Fellowship (2018–21) to establish his independent research program. In 2022 he began an NHMRC research fellowship at the University of Sydney, focussing on developing novel compounds for studying and treating disorders of the brain.
Medicinal Chemistry; Organic Synthesis; Chemical Biology; Neuroinflammation; Protein Aggregation; PET Imaging; Atherosclerosis; Supramolecular Chemistry; Molecular Topology.
| Project title | Research student |
|---|---|
| A PROTAC-BASED DEGRADATION OF TDP-43 IN THE TREATMENT AGAINST NEURODEGENERATIVE DISORDERS | Camelia BHATTACHARYYA |
| Targeting Central Vasopressin Receptors for the Treatment of Neuropsychiatric Disorders | Dan HAYES |
| Total synthesis of non-canonical strigolactones and marine ladder toxins | Fergus HENDERSON |
| P2X7 Antagonists and Their Role in Inflammation | Nick LYNCH |
| “PROTAxanes” – A novel solution “around” undruggable disease proteins | Bonnie ZHAN |
Publications
Expand all
Journals
- Garrett, T., Gilchrist, J., McKenzie, A., Ali, F., Danon, J., Werry, E., Kassiou, M. (2024). An Investigation on Linker Modifications of Cyanoguanidine-Based P2X7 Receptor Antagonists. ChemMedChem: chemistry enabling drug discovery, 19(17), e202400163. [More Information]
- Dhar, K., Townsend, B., Montgomery, A., Danon, J., Pagan, J., Kassiou, M. (2024). Enhancing CNS mitophagy: drug development and disease-relevant models. Trends In Pharmacological Sciences. [More Information]
- Alzghool, O., Aarnio, R., Helin, J., Wahlroos, S., Keller, T., Matilainen, M., Solis, J., Danon, J., Kassiou, M., Snellman, A., et al (2024). Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA. EJNMMI Research, 14(1). [More Information]
show 18 more
Edited Journals
- Alzghool, O., Aarnio, R., Helin, J., Wahlroos, S., Keller, T., Matilainen, M., Solis, J., Danon, J., Kassiou, M., Snellman, A., et al (2024). Correction to: Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA (EJNMMI Research, (2024), 14, 1, (25), 10.1186/s13550-024-01085-7). EJNMMI Research, 14(1). [More Information]
Expand all
2024
- Garrett, T., Gilchrist, J., McKenzie, A., Ali, F., Danon, J., Werry, E., Kassiou, M. (2024). An Investigation on Linker Modifications of Cyanoguanidine-Based P2X7 Receptor Antagonists. ChemMedChem: chemistry enabling drug discovery, 19(17), e202400163. [More Information]
- Alzghool, O., Aarnio, R., Helin, J., Wahlroos, S., Keller, T., Matilainen, M., Solis, J., Danon, J., Kassiou, M., Snellman, A., et al (2024). Correction to: Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA (EJNMMI Research, (2024), 14, 1, (25), 10.1186/s13550-024-01085-7). EJNMMI Research, 14(1). [More Information]
- Dhar, K., Townsend, B., Montgomery, A., Danon, J., Pagan, J., Kassiou, M. (2024). Enhancing CNS mitophagy: drug development and disease-relevant models. Trends In Pharmacological Sciences. [More Information]
show 3 more
2023
- Montgomery, A., Joyce, J., Danon, J., Kassiou, M. (2023). An update on late-stage functionalization in today’s drug discovery. Expert Opinion on Drug Discovery, 18(6), 597-613. [More Information]
- Castellino, N., Montgomery, A., Danon, J., Kassiou, M. (2023). Late-stage Functionalization for Improving Drug-like Molecular Properties. Chemical Reviews, 123(13), 8127-8153. [More Information]
2022
- Callis, T., Garrett, T., Montgomery, A., Danon, J., Kassiou, M. (2022). Recent Scaffold Hopping Applications in Central Nervous System Drug Discovery. Journal of Medicinal Chemistry, 65(20), 13483-13504. [More Information]
- Ma, B., Montgomery, A., Chen, B., Kassiou, M., Danon, J. (2022). Strategies for targeting the P2Y12 receptor in the central nervous system. Bioorganic & Medicinal Chemistry Letters, 71, 128837. [More Information]
- Cheng, H., Callis, T., Montgomery, A., Danon, J., Jorgensen, W., Ke, Y., Ittner, L., Werry, E., Kassiou, M. (2022). Understanding In Vitro Pathways to Drug Discovery for TDP-43 Proteinopathies. International Journal of Molecular Sciences, 23(23). [More Information]
2021
- Leigh, D., Danon, J., Fielden, S., Lemonnier, J., Whitehead, G., Woltering, S. (2021). A molecular endless (7 4 ) knot. Nature Chemistry, 13(2), 117-122. [More Information]
- Danon, J., Tregeagle, D., Kassiou, M. (2021). Adventures in Translocation: Studies of the Translocator Protein (TSPO) 18 kDa. Australian Journal of Chemistry, 74(11), 749-757. [More Information]
2020
- Sokias, R., Werry, E., Cheng, A., Lloyd, J., Sohler, G., Danon, J., Montgomery, A., Du, J., Gao, Q., Hibbs, D., Reekie, T., Kassiou, M., et al (2020). Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 207, 112725. [More Information]
2019
- Moir, M., Danon, J., Reekie, T., Kassiou, M. (2019). An overview of late-stage functionalization in today's drug discovery. Expert Opinion on Drug Discovery, 14(11), 1137-1149. [More Information]
- Danon, J., Reekie, T., Kassiou, M. (2019). Challenges and Opportunities in Central Nervous System Drug Discovery. Trends in Chemistry, 1(6), 612-624. [More Information]
- Ryan, P., Xu, M., Davey, A., Danon, J., Mellick, G., Kassiou, M., Rudrawar, S. (2019). O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease. ACS Chemical Neuroscience, 10(5), 2209-2221. [More Information]
2018
- Danon, J., Leigh, D., Pisano, S., Valero, A., Vitorica-Yrezabal, I. (2018). A Six-Crossing Doubly Interlocked [2]Catenane with Twisted Rings, and a Molecular Granny Knot. Angewandte Chemie - International Edition, 57(42), 13833-13837. [More Information]
2017
- Danon, J., Kruger, A., Leigh, D., Lemonnier, J., Stephens, A., Vitorica-Yrezabal, I., Woltering, S. (2017). Braiding a molecular knot with eight crossings. Science, 355(6321), 159-162. [More Information]
- Fletcher, J., Bartlett, G., Boyle, A., Danon, J., Rush, L., Lupas, A., Woolfson, D. (2017). N@a and N@d: Oligomer and partner specification by asparagine in coiled-coil interfaces. ACS Chemical Biology, 12(2), 528-538. [More Information]
2016
- Danon, J., Leigh, D., McGonigal, P., Ward, J., Wu, J. (2016). Triply-threaded [4]rotaxanes. Journal of the American Chemical Society, 138(38), 12643-12647. [More Information]
2015
- Beves, J., Danon, J., Leigh, D., Lemonnier, J., Vitorica-Yrezabal, I. (2015). A Solomon link through an interwoven molecular grid. Angewandte Chemie - International Edition, 54(26), 7555-7559. [More Information]
Selected Grants
2024
- 2024 EMCR Scheme, Danon J, Centre for Drug Discovery Innovation/EMCR Seed Funding
- Novel Ligands for TDP-43 to enable a PROTAC development platform to fight ALS, Gotsbacher M, Danon J, Kassiou M, The ALS Association/Research Grant
2023
- Innovative Molecules for Imaging Neuroinflammation, Danon J, Centre for Drug Discovery Innovation/Capability Access
- Innovative Molecules for Imaging Neuroinflammation, Danon J, Centre for Drug Discovery Innovation/Sydney SPARK Program 2023
show more
